Plasma Fractionation Market by Product (Immunoglobulins, Albumin, Protease Inhibitors, Von Willebrand Factor, PCC), Application (Neurology, Immunology, Hematology, Rheumatology), End User (Clinical Research, Hospitals & Clinics) & Region - Global Forecasts to 2027
Updated on : March 15, 2023
The global plasma fractionation market worth $36.3 billion by 2027, growing at a CAGR of 6.5% in the upcoming years.
The market size is updated for the base year of 2021 and forecasted from 2022 to 2027 by studying the impact of the overall plasma fractionation industry. The new version of the report includes ranges and scenarios, value chain analysis, ecosystem analysis, technology analysis, patent analysis, trends and disruptions impacting customers, Porter’s five forces analysis, and a regulatory landscape. In the earlier version of the report, 20 companies were profiled. In the updated version, a total of 25 companies have been profiled. Market growth is driven mainly by factors such as the growing use of immunoglobulins in various therapeutic areas, the rapidly growing geriatric population, and the rising prevalence of respiratory diseases and alpha-1-antitrypsin deficiency (AATD). However, high costs, limited reimbursements, and the market disruption caused by recombinant alternatives are expected to restrain the growth of this market to a certain extent during the forecast period.
To know about the assumptions considered for the study, Request for Free Sample Report
Plasma Fractionation Market Dynamics
Driver: Growing use of immunoglobulins for various therapeutic area
The increasing use of immunoglobulins for various therapeutic areas, such as autoimmune diseases, immune deficiencies, and infectious diseases, is driving the growth of the plasma fractionation market. Immunoglobulins are proteins produced by the immune system to fight against infections, allergies, and other diseases. Plasma fractionation processes are used to extract immunoglobulins from the plasma of healthy donors. These immunoglobulins are then used to treat various diseases, such as primary immunodeficiencies, autoimmune diseases, and infectious diseases. In addition, the increasing demand for immunoglobulins in the research sector is also driving the growth of the plasma fractionation market.
Restraint: Use of recombinant alternatives for certain plasma products
The use of recombinant alternatives for certain plasma products such as factor VIII, IX and von Willebrand factor is a key restraint for the growth of the plasma fractionation market. The advent of recombinant alternative products has enabled more efficient and cost-effective treatment of hemophilia, while also eliminating the risk of infections associated with the use of plasma-derived products. Numerous companies, such as Novo Nordisk, have launched recombinant alternative products in the market, which has significantly impacted the market of plasma-derived products.
Opportunity: Increased risk of communicable disease
The increasing risk of communicable diseases such as influenza, coronavirus, and HIV is expected to drive demand for plasma fractionation products. According to the World Health Organization (WHO), the number of reported cases of communicable diseases such as HIV, malaria, and tuberculosis has been increasing consistently over the past few decades. This has necessitated the need for more efficient and effective treatments and therapies for these diseases, which is expected to drive the demand for plasma fractionation products in the coming years.
Furthermore, according to the Centers for Disease Control and Prevention (CDC), there is an increasing risk of emerging and re-emerging diseases, which are caused by pathogens that have rapidly adapted to their environment. This has further increased the demand for high-quality plasma fractionation products, as these products can help in the prevention and treatment of such diseases. Additionally, the growing demand for plasma fractionation products for the manufacturing of biopharmaceuticals and vaccines is also expected to have a positive impact on the market growth.
Challenge: Stringent Government Regulations
The plasma fractionation market is highly regulated by government regulatory bodies such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). These organizations have stringent regulations for the approval and sale of plasma products. For instance, the FDA requires that manufacturers must comply with the Current Good Manufacturing Practice (cGMP) requirements as well as provide documentation such as product specifications, manufacturing and testing protocols, and safety data for plasma products before approval. Additionally, strict regulations on the collection and distribution of plasma also limit the market growth.
The immunoglobins segment will witness the highest growth in the plasma fractionation market during the forecast period.
Based on product, the market is segmented into immunoglobulins, coagulation factor concentrates, albumins, protease inhibitors, and other products. The immunoglobulins segment accounted for the largest share of the global market in 2021. This segment is also expected to register the highest CAGR during the forecast period. The high growth rate of this segment is attributed to the rising prevalence of neurological and immunological diseases, increasing off-label indications of IVIg, and the growing use of SCIg due to its ease of administration and reduced administration time. Immunoglobulins are also used to combat the effects of immunosenescence or age-related changes in immunity. With the growing prevalence of infections and disorders, the use of immunoglobulins is expected to increase in the coming years.
The neurology segment dominated the plasma fractionation market
Based on application, the market is segmented into neurology, immunology, hematology, critical care, pulmonology, hemato-oncology, rheumatology, and other applications. In 2021, the neurology segment accounted for the largest share of the market. This is mainly due to the increased application off immunoglobulin for chronic inflammatory demyelinating polyneuropathy (CIDP), multifocal motor neuropathy (MMN), myasthenia gravis, and inflammatory myopathies, shorter period response period of IVIG than steroids or oral immunosuppressants, rise in number of patients suffering from neurological disease, and increase research and development for use of IVIg for other indications related to neurology, including Alzheimer’s disease.
The hospitals & clinics segment dominated the plasma fractionation market
Based on end users, the market is segmented into hospitals & clinics, clinical research laboratories, and academic institutes. In 2021, the hospitals & clinics segment accounted for the largest share of the market. This is mainly due increasing adoption of plasma products in the treatment of various immunological, neurological, and bleeding disorders; the large patient pool treated in hospitals; the growing number of hospitals & clinics across the globe; and the increasing number of collaborations between the manufacturers of plasma products and hospitals.
To know about the assumptions considered for the study, download the pdf brochure
North America held the largest region of the plasma fractionation market.
Geographically, market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. In 2021, North America accounted for the largest share of the global market, followed by Europe and the Asia Pacific. The large share of North America in the global market is attributed to the high number of registered hemophilic patients, growing number of plasma collection centers, availability of paid plasma donation services, and expansion by leading market players in North America.
Key players in the global plasma fractionation market include CSL (Australia), Grifols, S.A. (Spain), Shire (US), Octapharma AG (Switzerland), Kedrion S.P.A (Italy), LFB (France), Biotest AG (Germany), Sanquin (Netherlands), China Biologic Products Holdings Inc. (China), GC Pharma (Korea), Bio Products Ltd. (UK), Japan Blood Products Organization (Japan), Emergent BioSolutions (US), Shanghai Raas Blood Products Co., Ltd. (China), Intas Pharmaceuticals Ltd. (India), Bharat Serum Vaccines Limited (India), SK Plasma (Korea), Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. (China), KabaFusion (US), Centurion Pharma (Istanbul), ADMA Biologics, Inc. (US), PlasmaGen BioSciences Pvt. Ltd. (India), Virchow Biotech Private Limited (India), Fusion Healthcare (India), and Hemarus Therapeutics Limited (India).
Plasma fractionation Market Report Scope
|
Report Metrics |
Details |
|
Market Revenue in 2022 |
$26.5 billion |
|
Estimated Value by 2027 |
$36.3 billion |
|
Growth Rate |
Poised to grow at a CAGR of 6.5% |
|
Market Segmentation |
Product, Application, End User & Region |
|
Market Driver |
Growing use of immunoglobulins for various therapeutic area |
|
Market Opportunity |
Increased risk of communicable disease |
|
Geographies Covered |
North America, Europe, APAC, MEA, and Latin America |
This research report categorizes the plasma fractionation market to forecast revenue and analyse trends in each of the following submarkets:
By Product
-
Immunoglobulins
- Intravenous Immunoglobulins
- Subcutaneous Immunoglobulins
- Other Immunoglobulins
-
Coagulation Factor Concentrates
- Factor VIII
- Factor IX
- Von Willebrand Factor
- Prothrombin Complex Concentrate
- Fibrinogen Concentrates
- Factor XIII
- Albumin
- Protease Inhibitors
-
Other Products
- Factor XI
By Application
- Neurology
- Immunology
- Hematology
- Critical care
- Pulmonology
- Hemato-oncology
- Rheumatology
- Other Applications
By End User
- Hospitals & Clinics
- Clinical Research Laboratories
- Academic Institutes
By Region
-
North America
- US
- Canada
-
Europe
- Germany
- France
- Italy
- Spain
- UK
- RoE
-
Asia Pacific
- China
- Japan
- Australia
- India
- Vietnam
- Indonesia
- Malaysia
- Rest of Asia Pacific
-
Latin America
- Brazil
- RoLATAM
-
Middle East & Africa
- Turkey
- Saudi Arabia
- Egypt
- UAE
- Rest of Middle East and Africa
Recent Developments
- Baxter International Inc. acquired ChemoSera S.A. in 2022. The acquisition will expand Baxter’s portfolio of plasma fractionation products and enable the company to expand its presence in the European markets.
- Biovian Oy acquired ViroClinics Biosciences B.V. in 2022. The acquisition will expand Biovian’s plasma fractionation capabilities, increase its global presence, and enable the company to enhance its offerings in the field of plasma-derived biopharmaceuticals.
- Takeda Pharmaceutical Company Limited acquired Shire Plc in 2022. This acquisition will broaden Takeda’s product portfolio, enabling the company to expand its presence in the plasma fractionation market.
- Grifols S.A. acquired Hologic Inc. in 2022. The acquisition of Hologic’s business will enable Grifols to expand its offering of plasma fractionation products and services, as well as its global presence.
- CSL Limited acquired Terumo BCT in 2023. This acquisition will enable CSL to expand its product portfolio and strengthen its position in the global plasma fractionation market.
Frequently Asked Questions (FAQs):
What is the projected market value of the global plasma fractionation market?
The global market of plasma fractionation is projected to reach USD 36.3 billion.
What is the estimated growth rate (CAGR) of the global plasma fractionation market for the next five years?
The global plasma fractionation market is projected to grow at a Compound Annual Growth Rate (CAGR) of 6.5% from 2022 to 2027.
What are the major revenue pockets in the plasma fractionation market currently?
Geographically, market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. In 2021, North America accounted for the largest share of the plasma fractionation market, followed by Europe and the Asia Pacific. The large share of North America in the global market is attributed to the high number of registered hemophilic patients, growing number of plasma collection centers, availability of paid plasma donation services, and expansion by leading market players in North America.
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
TABLE OF CONTENTS
1 INTRODUCTION (Page No. - 45)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 MARKET SCOPE
FIGURE 1 PLASMA FRACTIONATION MARKET
1.3.1 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY (Page No. - 49)
2.1 RESEARCH DATA
FIGURE 2 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
FIGURE 3 BREAKDOWN OF PRIMARIES BY RESPONDENT, DESIGNATION, AND REGION: GLOBAL MARKET
2.2 MARKET ESTIMATION METHODOLOGY
FIGURE 4 GLOBAL MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2021
FIGURE 5 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2021
2.2.1 INSIGHTS FROM PRIMARY EXPERTS
FIGURE 6 MARKET SIZE VALIDATION FROM PRIMARY SOURCES
2.3 MARKET GROWTH RATE PROJECTIONS
FIGURE 7 GLOBAL MARKET (SUPPLY SIDE): CAGR PROJECTIONS
FIGURE 8 GLOBAL MARKET (DEMAND SIDE): GROWTH ANALYSIS OF DEMAND-SIDE FACTORS
2.3.1 DATA TRIANGULATION
FIGURE 9 DATA TRIANGULATION METHODOLOGY
2.4 RESEARCH ASSUMPTIONS
2.4.1 COVID-19 ASSUMPTIONS
2.5 RISK ANALYSIS
3 EXECUTIVE SUMMARY (Page No. - 60)
FIGURE 10 PLASMA FRACTIONATION MARKET, BY PRODUCT, 2022 VS. 2027 (USD MILLION)
FIGURE 11 GLOBAL MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION)
FIGURE 12 GLOBAL MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)
FIGURE 13 GEOGRAPHICAL SNAPSHOT OF GLOBAL MARKET
4 PREMIUM INSIGHTS (Page No. - 63)
4.1 PLASMA FRACTIONATION MARKET OVERVIEW
FIGURE 14 GROWING USE OF IMMUNOGLOBULINS IN VARIOUS THERAPEUTIC AREAS TO DRIVE MARKET GROWTH
4.2 NORTH AMERICA: MARKET, BY PRODUCT & COUNTRY (2021)
FIGURE 15 IMMUNOGLOBULINS ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2021
4.3 GLOBAL MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 16 MALAYSIA TO REGISTER HIGHEST CAGR IN GLOBAL MARKET DURING FORECAST PERIOD
5 MARKET OVERVIEW (Page No. - 66)
5.1 INTRODUCTION
5.1.1 MARKET DYNAMICS
FIGURE 17 GLOBAL MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2 MARKET DYNAMICS
TABLE 1 GLOBAL MARKET: IMPACT ANALYSIS
5.2.1 MARKET DRIVERS
5.2.1.1 Growing use of immunoglobulins in various therapeutic areas
TABLE 2 OFF-LABEL INDICATIONS OF IVIG
TABLE 3 ON-LABEL INDICATIONS OF IVIG
TABLE 4 NUMBER OF CLINICAL STUDIES ON IMMUNOGLOBULINS, BY REGION (AS OF 2020–2021)
TABLE 5 NUMBER OF PATIENTS TREATED FOR TOP 15 TARGET CONDITIONS IN UK
5.2.1.2 Rapidly growing geriatric population
TABLE 6 GERIATRIC POPULATION, BY REGION, 2000−2050
5.2.1.3 Growing prevalence of respiratory diseases and AATD
5.2.1.4 New indications for plasma products
5.2.2 MARKET RESTRAINTS
5.2.2.1 High costs and limited reimbursements
5.2.2.2 Use of recombinant alternatives for certain plasma products
5.2.3 MARKET OPPORTUNITIES
5.2.3.1 Increased risk of communicable diseases
5.2.3.2 Rising prevalence of bleeding disorders
FIGURE 18 NUMBER OF HEMOPHILIA A AND HEMOPHILIA B PATIENTS WORLDWIDE, 2012–2018
TABLE 7 NUMBER OF HEMOPHILIA PATIENTS IN DEVELOPED AND EMERGING COUNTRIES, 2016 VS. 2018
5.2.4 MARKET CHALLENGES
5.2.4.1 Reduced supply of plasma due to low donor turnout
5.2.4.2 Stringent government regulations
5.3 IMPACT ASSESSMENT OF GLOBAL MARKET
FIGURE 19 SPECTRUM OF SCENARIOS BASED ON THE IMPACT OF UNCERTAINTIES ON THE GROWTH OF THE GLOBAL MARKET
5.4 PRICING ANALYSIS
TABLE 8 AVERAGE SELLING PRICE OF PLASMA FRACTIONATION PRODUCTS, BY KEY PLAYER, 2021 (USD)
TABLE 9 AVERAGE SELLING PRICE OF PLASMA FRACTIONATION PRODUCTS, BY REGION, 2021 (USD)
5.5 IMPACT OF COVID-19 ON MARKET DYNAMICS
5.5.1 DRIVERS AND OPPORTUNITIES
5.5.2 RESTRAINTS AND CHALLENGES
5.5.3 CUMULATIVE GROWTH ANALYSIS
5.5.4 OMICRON WAVE IMPACT ON MARKET
5.6 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
FIGURE 20 REVENUE SHIFT & NEW POCKETS FOR PLASMA FRACTIONATION PRODUCT PROVIDERS
5.7 VALUE CHAIN ANALYSIS
FIGURE 21 PROCEDURE OF PLASMA FRACTIONATION
FIGURE 22 VALUE CHAIN ANALYSIS OF THE GLOBAL MARKET
5.8 SUPPLY CHAIN ANALYSIS
FIGURE 23 GLOBAL MARKET: SUPPLY CHAIN ANALYSIS
5.9 ECOSYSTEM ANALYSIS
FIGURE 24 ECOSYSTEM ANALYSIS: GLOBAL MARKET
TABLE 10 SUPPLY CHAIN ECOSYSTEM
5.10 PATENT ANALYSIS
FIGURE 25 PATENT APPLICATIONS FOR THE GLOBAL MARKET, JANUARY 2012–MARCH 2022
5.11 KEY CONFERENCES AND EVENTS IN 2022–2023
TABLE 11 GLOBAL MARKET: LIST OF CONFERENCES AND EVENTS
5.12 REGULATORY ANALYSIS
5.12.1 LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS IN DIFFERENT REGIONS/COUNTRIES
5.12.2 REGULATORY SCENARIO IN DIFFERENT REGIONS/COUNTRIES
5.13 PORTER’S FIVE FORCES ANALYSIS
TABLE 12 GLOBAL MARKET: PORTER’S FIVE FORCES ANALYSIS
5.13.1 THREAT FROM NEW ENTRANTS
5.13.2 THREAT FROM SUBSTITUTES
5.13.3 BARGAINING POWER OF BUYERS
5.13.4 BARGAINING POWER OF SUPPLIERS
5.13.5 DEGREE OF COMPETITION
5.14 TECHNOLOGY ANALYSIS
5.14.1 COHN’S COLD ETHANOL PLASMA FRACTIONATION
5.14.2 GEL FILTRATION PLASMA FRACTIONATION
5.14.3 HUMAN PLASMA FRACTIONATION BY POLYETHYLENE GLYCOL
5.14.4 PLASMA FRACTIONATION BY AMMONIUM SULFATE
5.15 KEY STAKEHOLDERS AND BUYING CRITERIA
FIGURE 26 INFLUENCE OF STAKEHOLDERS IN THE BUYING PROCESS FOR PLASMA FRACTIONATION PRODUCTS
5.16 KEY BUYING CRITERIA BY END USERS
FIGURE 27 BUYING CRITERIA OF END USERS
5.17 PLASMA COLLECTION
5.17.1 US
5.17.2 CANADA
5.17.3 UK
5.17.4 JAPAN
5.17.5 INDIA
5.17.6 BRAZIL
5.18 PLASMA COLLECTION CENTERS
6 PLASMA FRACTIONATION MARKET, BY PRODUCT (Page No. - 100)
6.1 INTRODUCTION
TABLE 14 GLOBAL MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
6.2 IMMUNOGLOBULINS
TABLE 15 IVIG VS. SCIG THERAPY
TABLE 16 GLOBAL MARKET FOR IMMUNOGLOBULINS, BY REGION, 2020–2027 (USD MILLION)
TABLE 17 NORTH AMERICA: MARKET FOR IMMUNOGLOBULINS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 18 EUROPE: MARKET FOR IMMUNOGLOBULINS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 19 ASIA PACIFIC: MARKET FOR IMMUNOGLOBULINS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 20 LATIN AMERICA: MARKET FOR IMMUNOGLOBULINS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 21 MIDDLE EAST & AFRICA: MARKET FOR IMMUNOGLOBULINS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 22 GLOBAL MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2020–2027 (USD MILLION)
6.2.1 INTRAVENOUS IMMUNOGLOBULINS
6.2.1.1 IVIg to hold largest share of immunoglobulins market
TABLE 23 INTRAVENOUS IMMUNOGLOBULINS OFFERED BY KEY MARKET PLAYERS
TABLE 24 GLOBAL MARKET FOR INTRAVENOUS IMMUNOGLOBULINS, BY REGION, 2020–2027 (USD MILLION)
TABLE 25 NORTH AMERICA: MARKET FOR INTRAVENOUS IMMUNOGLOBULINS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 26 EUROPE: MARKET FOR INTRAVENOUS IMMUNOGLOBULINS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 27 ASIA PACIFIC: MARKET FOR INTRAVENOUS IMMUNOGLOBULINS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 28 LATIN AMERICA: MARKET FOR INTRAVENOUS IMMUNOGLOBULINS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 29 MIDDLE EAST & AFRICA: MARKET FOR INTRAVENOUS IMMUNOGLOBULINS, BY COUNTRY, 2020–2027 (USD MILLION)
6.2.2 SUBCUTANEOUS IMMUNOGLOBULINS
6.2.2.1 Benefits of self-administration and lower incidence of non-serious systemic adverse reactions to drive growth
TABLE 30 SUBCUTANEOUS IMMUNOGLOBULINS OFFERED BY KEY MARKET PLAYERS
TABLE 31 GLOBAL MARKET FOR SUBCUTANEOUS IMMUNOGLOBULINS, BY REGION, 2020–2027 (USD MILLION)
TABLE 32 NORTH AMERICA: MARKET FOR SUBCUTANEOUS IMMUNOGLOBULINS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 33 EUROPE: MARKET FOR SUBCUTANEOUS IMMUNOGLOBULINS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 34 ASIA PACIFIC: MARKET FOR SUBCUTANEOUS IMMUNOGLOBULINS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 35 LATIN AMERICA: MARKET FOR SUBCUTANEOUS IMMUNOGLOBULINS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 36 MIDDLE EAST & AFRICA: MARKET FOR SUBCUTANEOUS IMMUNOGLOBULINS, BY COUNTRY, 2020–2027 (USD MILLION)
6.2.3 OTHER IMMUNOGLOBULINS
TABLE 37 OTHER IMMUNOGLOBULINS OFFERED BY KEY MARKET PLAYERS
TABLE 38 GLOBAL MARKET FOR OTHER IMMUNOGLOBULINS, BY REGION, 2020–2027 (USD MILLION)
TABLE 39 NORTH AMERICA: MARKET FOR OTHER IMMUNOGLOBULINS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 40 EUROPE: MARKET FOR OTHER IMMUNOGLOBULINS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 41 ASIA PACIFIC: MARKET FOR OTHER IMMUNOGLOBULINS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 42 LATIN AMERICA: MARKET FOR OTHER IMMUNOGLOBULINS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 43 MIDDLE EAST & AFRICA: MARKET FOR OTHER IMMUNOGLOBULINS, BY COUNTRY, 2020–2027 (USD MILLION)
6.3 COAGULATION FACTOR CONCENTRATES
TABLE 44 GLOBAL MARKET FOR COAGULATION FACTOR CONCENTRATES, BY REGION, 2020–2027 (USD MILLION)
TABLE 45 NORTH AMERICA: MARKET FOR COAGULATION FACTOR CONCENTRATES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 46 EUROPE: MARKET FOR COAGULATION FACTOR CONCENTRATES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 47 ASIA PACIFIC: MARKET FOR COAGULATION FACTOR CONCENTRATES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 48 LATIN AMERICA: MARKET FOR COAGULATION FACTOR CONCENTRATES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 49 MIDDLE EAST & AFRICA: MARKET FOR COAGULATION FACTOR CONCENTRATES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 50 GLOBAL MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION)
6.3.1 FACTOR VIII
6.3.1.1 Factor VIII to hold largest share of coagulation factor concentrates market
TABLE 51 FACTOR VIII OFFERED BY KEY MARKET PLAYERS
TABLE 52 GLOBAL MARKET FOR FACTOR VIII, BY REGION, 2020–2027 (USD MILLION)
TABLE 53 NORTH AMERICA: MARKET FOR FACTOR VIII, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 54 EUROPE: MARKET FOR FACTOR VIII, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 55 ASIA PACIFIC: MARKET FOR FACTOR VIII, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 56 LATIN AMERICA: MARKET FOR FACTOR VIII, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 57 MIDDLE EAST & AFRICA: MARKET FOR FACTOR VIII, BY COUNTRY, 2020–2027 (USD MILLION)
6.3.2 FACTOR IX
6.3.2.1 Routine use of human plasma-derived factor IX (pdFIX) concentrates in hemophilia treatment to aid growth
TABLE 58 FACTOR IX OFFERED BY KEY MARKET PLAYERS
TABLE 59 GLOBAL MARKET FOR FACTOR IX, BY REGION, 2020–2027 (USD MILLION)
TABLE 60 NORTH AMERICA: MARKET FOR FACTOR IX, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 61 EUROPE: MARKET FOR FACTOR IX, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 62 ASIA PACIFIC: MARKET FOR FACTOR IX, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 63 LATIN AMERICA: MARKET FOR FACTOR IX, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 64 MIDDLE EAST & AFRICA: MARKET FOR FACTOR IX, BY COUNTRY, 2020–2027 (USD MILLION)
6.3.3 VON WILLEBRAND FACTOR
6.3.3.1 Growing rate of early diagnosis to drive segment
TABLE 65 VON WILLEBRAND FACTOR OFFERED BY KEY MARKET PLAYERS
TABLE 66 GLOBAL MARKET FOR VON WILLEBRAND FACTOR, BY REGION, 2020–2027 (USD MILLION)
TABLE 67 NORTH AMERICA: MARKET FOR VON WILLEBRAND FACTOR, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 68 EUROPE: MARKET FOR VON WILLEBRAND FACTOR, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 69 ASIA PACIFIC: MARKET FOR VON WILLEBRAND FACTOR, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 70 LATIN AMERICA: MARKET FOR VON WILLEBRAND FACTOR, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 71 MIDDLE EAST & AFRICA: MARKET FOR VON WILLEBRAND FACTOR, BY COUNTRY, 2020–2027 (USD MILLION)
6.3.4 PROTHROMBIN COMPLEX CONCENTRATES
6.3.4.1 Advantages of PCC over fresh frozen plasma to support market
TABLE 72 PROTHROMBIN COMPLEX CONCENTRATES OFFERED BY KEY MARKET PLAYERS
TABLE 73 GLOBAL MARKET FOR PROTHROMBIN COMPLEX CONCENTRATES, BY REGION, 2020–2027 (USD MILLION)
TABLE 74 NORTH AMERICA: MARKET FOR PROTHROMBIN COMPLEX CONCENTRATES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 75 EUROPE: MARKET FOR PROTHROMBIN COMPLEX CONCENTRATES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 76 ASIA PACIFIC: MARKET FOR PROTHROMBIN COMPLEX CONCENTRATES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 77 LATIN AMERICA: MARKET FOR PROTHROMBIN COMPLEX CONCENTRATES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 78 MIDDLE EAST & AFRICA: MARKET FOR PROTHROMBIN COMPLEX CONCENTRATES, BY COUNTRY, 2020–2027 (USD MILLION)
6.3.5 FIBRINOGEN CONCENTRATES
6.3.5.1 Safety profile, accuracy, and speed of administration are key advantages of fibrinogen concentrates
TABLE 79 FIBRINOGEN CONCENTRATES OFFERED BY KEY MARKET PLAYERS
TABLE 80 GLOBAL MARKET FOR FIBRINOGEN CONCENTRATES, BY REGION, 2020–2027 (USD MILLION)
TABLE 81 NORTH AMERICA: MARKET FOR FIBRINOGEN CONCENTRATES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 82 EUROPE: MARKET FOR FIBRINOGEN CONCENTRATES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 83 ASIA PACIFIC: MARKET FOR FIBRINOGEN CONCENTRATES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 84 LATIN AMERICA: MARKET FOR FIBRINOGEN CONCENTRATES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 85 MIDDLE EAST & AFRICA: MARKET FOR FIBRINOGEN CONCENTRATES, BY COUNTRY, 2020–2027 (USD MILLION)
6.3.6 FACTOR XIII
6.3.6.1 Applications in treating rare bleeding disorders to contribute to demand
TABLE 86 FACTOR XIII OFFERED BY KEY MARKET PLAYERS
TABLE 87 GLOBAL MARKET FOR FACTOR XIII, BY REGION, 2020–2027 (USD MILLION)
TABLE 88 NORTH AMERICA: MARKET FOR FACTOR XIII, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 89 EUROPE: MARKET FOR FACTOR XIII, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 90 ASIA PACIFIC: MARKET FOR FACTOR XIII, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 91 LATIN AMERICA: MARKET FOR FACTOR XIII, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 92 MIDDLE EAST & AFRICA: MARKET FOR FACTOR XIII, BY COUNTRY, 2020–2027 (USD MILLION)
6.3.7 FACTOR XI
6.3.7.1 Growing demand for factor XI to treat bleeding disorders in patients to drive growth
TABLE 93 GLOBAL MARKET FOR FACTOR XI, BY REGION, 2020–2027 (USD MILLION)
TABLE 94 NORTH AMERICA: MARKET FOR FACTOR XI, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 95 EUROPE: MARKET FOR FACTOR XI, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 96 ASIA PACIFIC: MARKET FOR FACTOR XI, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 97 LATIN AMERICA: MARKET FOR FACTOR XI, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 98 MIDDLE EAST & AFRICA: MARKET FOR FACTOR XI, BY COUNTRY, 2020–2027 (USD MILLION)
6.4 ALBUMIN
6.4.1 RISING DEMAND FOR ALBUMIN AS AN ANTIOXIDANT TO FUEL MARKET
TABLE 99 ALBUMIN OFFERED BY KEY MARKET PLAYERS
TABLE 100 GLOBAL MARKET FOR ALBUMIN, BY REGION, 2020–2027 (USD MILLION)
TABLE 101 NORTH AMERICA: MARKET FOR ALBUMIN, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 102 EUROPE: MARKET FOR ALBUMIN, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 103 ASIA PACIFIC: MARKET FOR ALBUMIN, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 104 LATIN AMERICA: MARKET FOR ALBUMIN, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 105 MIDDLE EAST & AFRICA: MARKET FOR ALBUMIN, BY COUNTRY, 2020–2027 (USD MILLION)
6.5 PROTEASE INHIBITORS
6.5.1 RISING PREVALENCE OF COPD TO DRIVE DEMAND FOR PROTEASE INHIBITORS
TABLE 106 PROTEASE INHIBITORS OFFERED BY KEY MARKET PLAYERS
TABLE 107 GLOBAL MARKET FOR PROTEASE INHIBITORS, BY REGION, 2020–2027 (USD MILLION)
TABLE 108 NORTH AMERICA: MARKET FOR PROTEASE INHIBITORS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 109 EUROPE: MARKET FOR PROTEASE INHIBITORS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 110 ASIA PACIFIC: MARKET FOR PROTEASE INHIBITORS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 111 LATIN AMERICA: MARKET FOR PROTEASE INHIBITORS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 112 MIDDLE EAST & AFRICA: MARKET FOR PROTEASE INHIBITORS, BY COUNTRY, 2020–2027 (USD MILLION)
6.6 OTHER PLASMA PRODUCTS
TABLE 113 GLOBAL MARKET FOR OTHER PLASMA PRODUCTS, BY REGION, 2020–2027 (USD MILLION)
TABLE 114 NORTH AMERICA: MARKET FOR OTHER PLASMA PRODUCTS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 115 EUROPE: MARKET FOR OTHER PLASMA PRODUCTS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 116 ASIA PACIFIC: MARKET FOR OTHER PLASMA PRODUCTS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 117 LATIN AMERICA: MARKET FOR OTHER PLASMA PRODUCTS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 118 MIDDLE EAST & AFRICA: MARKET FOR OTHER PLASMA PRODUCTS, BY COUNTRY, 2020–2027 (USD MILLION)
7 PLASMA FRACTIONATION MARKET, BY APPLICATION (Page No. - 160)
7.1 INTRODUCTION
TABLE 119 GLOBAL MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
7.2 NEUROLOGY
7.2.1 RISING PREVALENCE OF MAJOR AGE-RELATED NEUROLOGICAL DISORDERS TO DRIVE MARKET GROWTH
TABLE 120 NUMBER OF DALYS FOR NEUROLOGICAL DISORDERS AND THE PERCENTAGE OF DALYS PROJECTED FOR 2005, 2015, AND 2030
TABLE 121 PLASMA-DERIVED PRODUCTS AND APPLICATIONS IN NEUROLOGY
TABLE 122 GLOBAL MARKET FOR NEUROLOGY APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
TABLE 123 NORTH AMERICA: MARKET FOR NEUROLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 124 EUROPE: MARKET FOR NEUROLOGY APPLICATIONS, 2020–2027 (USD MILLION)
TABLE 125 ASIA PACIFIC: MARKET FOR NEUROLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 126 LATIN AMERICA: MARKET FOR NEUROLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 127 MIDDLE EAST & AFRICA: MARKET FOR NEUROLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
7.3 IMMUNOLOGY
7.3.1 ADVANCEMENTS IN PIDS RESEARCH TO OFFER NEW OPPORTUNITIES FOR GROWTH
TABLE 129 LIST OF FDA-APPROVED INDICATIONS FOR IMMUNOGLOBULINS IN IMMUNOLOGY
TABLE 130 DIAGNOSIS DISTRIBUTION OF DIFFERENT CATEGORIES OF PRIMARY IMMUNODEFICIENCY DISEASE
TABLE 131 PREVALENCE OF PRIMARY IMMUNODEFICIENCY DISEASE, BY REGION, 2013 VS. 2015
TABLE 132 PLASMA-DERIVED PRODUCTS AND THEIR APPLICATIONS IN IMMUNOLOGY
TABLE 133 GLOBAL MARKET FOR IMMUNOLOGY APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
TABLE 134 NORTH AMERICA: MARKET FOR IMMUNOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 135 EUROPE: MARKET FOR IMMUNOLOGY APPLICATIONS, 2020–2027 (USD MILLION)
TABLE 136 ASIA PACIFIC: MARKET FOR IMMUNOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 137 LATIN AMERICA: MARKET FOR IMMUNOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 138 MIDDLE EAST & AFRICA: MARKET FOR IMMUNOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
7.4 HEMATOLOGY
7.4.1 GROWING NUMBER OF HEMOPHILIA PATIENTS TO DRIVE DEMAND FOR COAGULATION FACTOR CONCENTRATES
TABLE 139 NUMBER OF IDENTIFIED PATIENTS, BY INDICATION, 2020
TABLE 140 NUMBER OF HEMOPHILIA PATIENTS (2012–2020)
FIGURE 29 DISTRIBUTION OF HEMOPHILIA PATIENTS, BY REGION, 2021
TABLE 141 GLOBAL MARKET FOR HEMATOLOGY APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
TABLE 142 NORTH AMERICA: MARKET FOR HEMATOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 143 EUROPE: MARKET FOR HEMATOLOGY APPLICATIONS, 2020–2027 (USD MILLION)
TABLE 144 ASIA PACIFIC: MARKET FOR HEMATOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 145 LATIN AMERICA: MARKET FOR HEMATOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 146 MIDDLE EAST & AFRICA: MARKET FOR HEMATOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
7.5 CRITICAL CARE
7.5.1 INCREASING OFF-LABEL USE OF ALBUMIN TO DRIVE DEMAND FOR PLASMA-DERIVED CRITICAL CARE PRODUCTS
TABLE 147 PLASMA-DERIVED PRODUCTS AND APPLICATIONS IN CRITICAL CARE
TABLE 148 GLOBAL MARKET FOR CRITICAL CARE APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
TABLE 149 NORTH AMERICA: MARKET FOR CRITICAL CARE APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 150 EUROPE: MARKET FOR CRITICAL CARE APPLICATIONS, 2020–2027 (USD MILLION)
TABLE 151 ASIA PACIFIC: MARKET FOR CRITICAL CARE APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 152 LATIN AMERICA: MARKET FOR CRITICAL CARE APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 153 MIDDLE EAST & AFRICA: MARKET FOR CRITICAL CARE APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
7.6 PULMONOLOGY
7.6.1 RISING PREVALENCE OF ALPHA-1-ANTITRYPSIN DEFICIENCY AND COPD TO DRIVE MARKET
TABLE 154 PLASMA-DERIVED PRODUCTS AND APPLICATIONS IN PULMONOLOGY
TABLE 155 GLOBAL MARKET FOR PULMONOLOGY APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
TABLE 156 NORTH AMERICA: MARKET FOR PULMONOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 157 EUROPE: MARKET FOR PULMONOLOGY APPLICATIONS, 2020–2027 (USD MILLION)
TABLE 158 ASIA PACIFIC: MARKET FOR PULMONOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 159 LATIN AMERICA: MARKET FOR PULMONOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 160 MIDDLE EAST & AFRICA: MARKET FOR PULMONOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
7.7 HEMATO-ONCOLOGY
7.7.1 RISING NUMBER OF BLOOD CANCER PATIENTS TO DRIVE DEMAND FOR PLASMA-DERIVED PRODUCTS
TABLE 161 INCIDENCE OF LEUKEMIA, MULTIPLE MYELOMA, AND HODGKIN’S LYMPHOMA, BY REGION, 2012−2018
TABLE 162 PLASMA-DERIVED PRODUCTS AND APPLICATIONS IN HEMATO-ONCOLOGY
TABLE 163 GLOBAL MARKET FOR HEMATO-ONCOLOGY APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
TABLE 164 NORTH AMERICA: MARKET FOR HEMATO-ONCOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 165 EUROPE: MARKET FOR HEMATO-ONCOLOGY APPLICATIONS, 2020–2027 (USD MILLION)
TABLE 166 ASIA PACIFIC: MARKET FOR HEMATO-ONCOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 167 LATIN AMERICA: MARKET FOR HEMATO-ONCOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 168 MIDDLE EAST & AFRICA: MARKET FOR HEMATO-ONCOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
7.8 RHEUMATOLOGY
7.8.1 INCREASING PREVALENCE OF RHEUMATIC CONDITIONS TO DRIVE MARKET FOR RHEUMATOLOGY
TABLE 169 GLOBAL MARKET FOR RHEUMATOLOGY APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
TABLE 170 NORTH AMERICA: MARKET FOR RHEUMATOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 171 EUROPE: MARKET FOR RHEUMATOLOGY APPLICATIONS, 2020–2027 (USD MILLION)
TABLE 172 ASIA PACIFIC: MARKET FOR RHEUMATOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 173 LATIN AMERICA: MARKET FOR RHEUMATOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 174 MIDDLE EAST & AFRICA: MARKET FOR RHEUMATOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
7.9 OTHER APPLICATIONS
TABLE 175 PLASMA-DERIVED PRODUCTS FOR OTHER APPLICATIONS
TABLE 176 GLOBAL MARKET FOR OTHER APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
TABLE 177 NORTH AMERICA: MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 178 EUROPE: MARKET FOR OTHER APPLICATIONS, 2020–2027 (USD MILLION)
TABLE 179 ASIA PACIFIC: MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 180 LATIN AMERICA: MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 181 MIDDLE EAST & AFRICA: MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
8 PLASMA FRACTIONATION MARKET, BY END USER (Page No. - 189)
8.1 INTRODUCTION
TABLE 182 GLOBAL MARKET, BY END USER, 2020–2027 (USD MILLION)
8.2 HOSPITALS & CLINICS
8.2.1 GROWING NUMBER OF SURGERIES TO PROPEL ADOPTION OF PLASMA-DERIVED PRODUCTS
TABLE 183 GLOBAL MARKET FOR HOSPITALS & CLINICS, BY REGION, 2020–2027 (USD MILLION)
TABLE 184 NORTH AMERICA: MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 185 EUROPE: MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 186 ASIA PACIFIC: MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 187 LATIN AMERICA: MARKET FOR HOSPITALS & CLINICS, 2020–2027 (USD MILLION)
TABLE 188 MIDDLE EAST & AFRICA: MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2020–2027 (USD MILLION)
8.3 CLINICAL RESEARCH LABORATORIES
8.3.1 INCREASING CLINICAL STUDIES ON NEW INDICATIONS FOR PLASMA-DERIVED PRODUCTS TO DRIVE GROWTH
TABLE 189 GLOBAL MARKET FOR CLINICAL RESEARCH LABORATORIES, BY REGION, 2020–2027 (USD MILLION)
TABLE 190 NORTH AMERICA: MARKET FOR CLINICAL RESEARCH LABORATORIES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 191 EUROPE: MARKET FOR CLINICAL RESEARCH LABORATORIES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 192 ASIA PACIFIC: MARKET FOR CLINICAL RESEARCH LABORATORIES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 193 LATIN AMERICA: MARKET FOR CLINICAL RESEARCH LABORATORIES, 2020–2027 (USD MILLION)
TABLE 194 MIDDLE EAST & AFRICA: MARKET FOR CLINICAL RESEARCH LABORATORIES, BY COUNTRY, 2020–2027 (USD MILLION)
8.4 ACADEMIC INSTITUTES
8.4.1 GROWING STUDIES ON SAFETY AND EFFICACY OF PLASMA-DERIVED PRODUCTS TO PROPEL MARKET
TABLE 195 GLOBAL MARKET FOR ACADEMIC INSTITUTES, BY REGION, 2020–2027 (USD MILLION)
TABLE 196 NORTH AMERICA: MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 197 EUROPE: MARKET FOR ACADEMIC INSTITUTES, 2020–2027 (USD MILLION)
TABLE 198 ASIA PACIFIC: MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 199 LATIN AMERICA: MARKET FOR ACADEMIC INSTITUTES BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 200 MIDDLE EAST & AFRICA: MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION)
9 PLASMA FRACTIONATION MARKET, BY REGION (Page No. - 199)
9.1 INTRODUCTION
TABLE 201 GLOBAL MARKET, BY REGION, 2020–2027 (USD MILLION)
9.2 NORTH AMERICA
FIGURE 30 NORTH AMERICA: PLASMA FRACTIONATION MARKET SNAPSHOT
TABLE 202 NORTH AMERICA: MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 203 NORTH AMERICA: MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 204 NORTH AMERICA: MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 205 NORTH AMERICA: MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 206 NORTH AMERICA: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 207 NORTH AMERICA: MARKET, BY END USER, 2020–2027 (USD MILLION)
9.2.1 US
9.2.1.1 US to dominate market for plasma fractionation products
TABLE 208 US: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 209 US: MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 210 US: MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 211 US: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 212 US: MARKET, BY END USER, 2020–2027 (USD MILLION)
9.2.2 CANADA
9.2.2.1 High per capita usage of IVIg in Canada—a key factor driving market growth
TABLE 213 CANADA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 214 CANADA: MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 215 CANADA: MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 216 CANADA: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 217 CANADA: MARKET, BY END USER, 2020–2027 (USD MILLION)
9.3 EUROPE
TABLE 218 EUROPE: PLASMA FRACTIONATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 219 EUROPE: MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 220 EUROPE: MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 221 EUROPE: MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 222 EUROPE: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 223 EUROPE: MARKET, BY END USER, 2020–2027 (USD MILLION)
9.3.1 GERMANY
9.3.1.1 Highest plasma fractionation capacity in Europe to drive market in Germany
TABLE 224 GERMANY: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 225 GERMANY: MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 226 GERMANY: MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 227 GERMANY: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 228 GERMANY: MARKET, BY END USER, 2020–2027 (USD MILLION)
9.3.2 UK
9.3.2.1 Increasing incidence of hemophilia and lift on ban of plasma donation to drive market
TABLE 229 UK: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 230 UK: MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 231 UK: MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 232 UK: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 233 UK: MARKET, BY END USER, 2020–2027 (USD MILLION)
9.3.3 FRANCE
9.3.3.1 High prevalence of bleeding disorders to drive market
TABLE 234 NUMBER OF PEOPLE WITH BLEEDING DISORDERS IN FRANCE, 2012–2020
TABLE 235 FRANCE: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 236 FRANCE: MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 237 FRANCE: MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 238 FRANCE: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 239 FRANCE: MARKET, BY END USER, 2020–2027 (USD MILLION)
9.3.4 ITALY
9.3.4.1 Growth in geriatric population to drive demand for plasma fractionation
TABLE 240 PRODUCTION OF PLASMA PRODUCTS IN ITALY (2013, 2018, AND 2023-E)
TABLE 241 ITALY: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 242 ITALY: MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 243 ITALY: MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 244 ITALY: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 245 ITALY: MARKET, BY END USER, 2020–2027 (USD MILLION)
9.3.5 SPAIN
9.3.5.1 Growing demand for plasma products for treatment of chronic diseases in elderly to spur market growth
TABLE 246 SPAIN: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 247 SPAIN: MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 248 SPAIN: MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 249 SPAIN: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 250 SPAIN: MARKET, BY END USER, 2020–2027 (USD MILLION)
9.3.6 REST OF EUROPE
TABLE 251 REST OF EUROPE: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 252 REST OF EUROPE: MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 253 REST OF EUROPE: MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 254 REST OF EUROPE: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 255 REST OF EUROPE: MARKET, BY END USER, 2020–2027 (USD MILLION)
9.4 ASIA PACIFIC
TABLE 256 ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 257 ASIA PACIFIC: MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 258 ASIA PACIFIC: MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 259 ASIA PACIFIC: MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 260 ASIA PACIFIC: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 261 ASIA PACIFIC: MARKET, BY END USER, 2020–2027 (USD MILLION)
9.4.1 CHINA
9.4.1.1 Rising incidence of diseases such as liver cancer and hepatitis B to drive market
TABLE 262 CHINA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 263 CHINA: MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 264 CHINA: MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 265 CHINA: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 266 CHINA: MARKET, BY END USER, 2020–2027 (USD MILLION)
9.4.2 JAPAN
9.4.2.1 Rising prevalence of neurological disorders and hematological diseases to support market
TABLE 267 MEAN PER CAPITA FACTOR VIII AND IX USE IN JAPAN, 2014 VS. 2018 (IN IU/TOTAL POPULATION)
TABLE 268 PATIENTS WITH BLEEDING DISORDERS IN JAPAN, 2014 VS. 2020
TABLE 269 JAPAN: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 270 JAPAN: MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 271 JAPAN: MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 272 JAPAN: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 273 JAPAN: MARKET, BY END USER, 2020–2027 (USD MILLION)
9.4.3 AUSTRALIA
9.4.3.1 Growing demand for plasma products for treatment of chronic diseases to aid growth
TABLE 274 TOTAL IG (GRAMS) USED IN AUSTRALIA, 2008/09–2017/18
TABLE 275 AUSTRALIA: BLOOD SECTOR OVERVIEW (2017–2018)
TABLE 276 AUSTRALIA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 277 AUSTRALIA: MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 278 AUSTRALIA: MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 279 AUSTRALIA: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 280 AUSTRALIA: MARKET, BY END USER, 2020–2027 (USD MILLION)
9.4.4 INDIA
9.4.4.1 Growing healthcare awareness, availability of better diagnostic tools, and rising geriatric population to propel market
TABLE 281 INDIA: NUMBER OF PATIENTS WITH BLEEDING DISORDERS, 2012–2020
TABLE 282 INDIA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 283 INDIA: MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 284 INDIA: MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 285 INDIA: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 286 INDIA: MARKET, BY END USER, 2020–2027 (USD MILLION)
9.4.5 VIETNAM
9.4.5.1 Growing pool of patients suffering from COPD, PID, and bleeding disorders to boost market
TABLE 287 VIETNAM: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 288 VIETNAM: MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 289 VIETNAM: MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 290 VIETNAM: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 291 VIETNAM: MARKET, BY END USER, 2020–2027 (USD MILLION)
9.4.6 INDONESIA
9.4.6.1 Growing government initiatives to boost market
TABLE 292 INDONESIA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 293 INDONESIA: MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 294 INDONESIA: MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 295 INDONESIA: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 296 INDONESIA: MARKET, BY END USER, 2020–2027 (USD MILLION)
9.4.7 MALAYSIA
9.4.7.1 Increasing prevalence of bleeding disorders to support growth
TABLE 297 MALAYSIA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 298 MALAYSIA: MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 299 MALAYSIA: MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 300 MALAYSIA: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 301 MALAYSIA: MARKET, BY END USER, 2020–2027 (USD MILLION)
9.4.8 REST OF ASIA PACIFIC
TABLE 302 REST OF ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 303 REST OF ASIA PACIFIC: MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 304 REST OF ASIA PACIFIC: MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 305 REST OF ASIA PACIFIC: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 306 REST OF ASIA PACIFIC: MARKET, BY END USER, 2020–2027 (USD MILLION)
9.5 LATIN AMERICA
TABLE 307 LATIN AMERICA: PLASMA FRACTIONATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 308 LATIN AMERICA: MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 309 LATIN AMERICA: MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 310 LATIN AMERICA: MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 311 LATIN AMERICA: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 312 LATIN AMERICA: MARKET, BY END USER, 2020–2027 (USD MILLION)
9.5.1 BRAZIL
9.5.1.1 Growth of vaccine manufacturing to fuel growth
TABLE 313 BRAZIL: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 314 BRAZIL: MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 315 BRAZIL: MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 316 BRAZIL: MARKET BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 317 BRAZIL: MARKET, BY END USER, 2020–2027 (USD MILLION)
9.5.2 REST OF LATIN AMERICA
TABLE 318 REST OF LATIN AMERICA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 319 REST OF LATIN AMERICA: MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 320 REST OF LATIN AMERICA: MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 321 REST OF LATIN AMERICA: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 322 REST OF LATIN AMERICA: MARKET, BY END USER, 2020–2027 (USD MILLION)
9.6 MIDDLE EAST & AFRICA
TABLE 323 HEMOPHILIA PATIENTS IN MIDDLE EAST & AFRICA, BY COUNTRY, 2012–2020
TABLE 324 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 325 MIDDLE EAST & AFRICA: MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 326 MIDDLE EAST & AFRICA: MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 327 MIDDLE EAST & AFRICA: MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 328 MIDDLE EAST & AFRICA: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 329 MIDDLE EAST & AFRICA: MARKET, BY END USER, 2020–2027 (USD MILLION)
9.6.1 TURKEY
9.6.1.1 Turkey to dominate plasma fractionation market in Middle East & Africa
TABLE 330 TURKEY: DEMOGRAPHIC INDICATORS
TABLE 331 TURKEY: MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 332 TURKEY: MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 333 TURKEY: MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 334 TURKEY: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 335 TURKEY: MARKET, BY END USER, 2020–2027 (USD MILLION)
9.6.2 SAUDI ARABIA
9.6.2.1 Developments in healthcare infrastructure to support growth
TABLE 336 SAUDI ARABIA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 337 SAUDI ARABIA: MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 338 SAUDI ARABIA: MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 339 SAUDI ARABIA: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 340 SAUDI ARABIA: MARKET, BY END USER, 2020–2027 (USD MILLION)
9.6.3 EGYPT
9.6.3.1 Growing research on plasma and plasma derivatives to support market growth
TABLE 341 EGYPT: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 342 EGYPT: MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 343 EGYPT: MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 344 EGYPT: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 345 EGYPT: MARKET, BY END USER, 2020–2027 (USD MILLION)
9.6.4 UAE
9.6.4.1 Growing government initiatives for healthcare infrastructure development to drive market in UAE
TABLE 346 UAE: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 347 UAE: MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 348 UAE: MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 349 UAE: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 350 UAE: MARKET, BY END USER, 2020–2027 (USD MILLION)
9.6.5 REST OF MIDDLE EAST & AFRICA
TABLE 351 HEMOPHILIA PATIENTS IN REST OF MIDDLE EAST & AFRICA, 2012 VS. 2017 VS. 2018
TABLE 352 REST OF MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 353 REST OF MIDDLE EAST & AFRICA: MARKET FOR IMMUNOGLOBULINS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 354 REST OF MIDDLE EAST & AFRICA: MARKET FOR COAGULATION FACTOR CONCENTRATES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 355 REST OF MIDDLE EAST & AFRICA: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 356 REST OF MIDDLE EAST & AFRICA: MARKET, BY END USER, 2020–2027 (USD MILLION)
10 COMPETITIVE LANDSCAPE (Page No. - 270)
10.1 OVERVIEW
10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
FIGURE 32 KEY PLAYER STRATEGIES IN PLASMA FRACTIONATION MARKET, 2018–2022
10.3 MARKET SHARE ANALYSIS
FIGURE 33 GLOBAL MARKET: MARKET SHARE ANALYSIS, 2021 (TOP 5 PLAYERS)
TABLE 357 GLOBAL MARKET: DEGREE OF COMPETITION
10.4 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
FIGURE 34 REVENUE SHARE ANALYSIS OF PLAYERS IN GLOBAL MARKET (TOP 5)
10.5 COMPANY EVALUATION QUADRANT
10.5.1 STARS
10.5.2 EMERGING LEADERS
10.5.3 PERVASIVE PLAYERS
10.5.4 PARTICIPANTS
FIGURE 35 GLOBAL MARKET: COMPANY EVALUATION QUADRANT, 2021
10.6 COMPANY EVALUATION QUADRANT: START-UPS/SMES
10.6.1 PROGRESSIVE COMPANIES
10.6.2 STARTING BLOCKS
10.6.3 RESPONSIVE COMPANIES
10.6.4 DYNAMIC COMPANIES
FIGURE 36 GLOBAL MARKET: COMPANY EVALUATION QUADRANT FOR START-UPS/SMES, 2021
10.7 COMPETITIVE BENCHMARKING
10.7.1 COMPANY PRODUCT FOOTPRINT (25 COMPANIES)
TABLE 358 PRODUCT FOOTPRINT ANALYSIS OF KEY PLAYERS IN GLOBAL MARKET:
10.7.2 COMPANY PRODUCT FOOTPRINT (25 COMPANIES)
TABLE 359 PRODUCT PORTFOLIO ANALYSIS: GLOBAL MARKET (2021)
10.7.3 COMPANY GEOGRAPHIC FOOTPRINT (25 COMPANIES)
TABLE 360 GEOGRAPHIC REVENUE MIX: GLOBAL MARKET (2021)
10.8 COMPETITIVE SCENARIO AND TRENDS
TABLE 361 PRODUCT LAUNCHES & APPROVALS, JANUARY 2018–APRIL 2022
TABLE 362 DEALS, JANUARY 2018–APRIL 2022
TABLE 363 OTHER DEVELOPMENTS, JANUARY 2018–APRIL 2022
10.9 COMPETITIVE BENCHMARKING
TABLE 364 GLOBAL MARKET: DETAILED LIST OF KEY START-UPS/SMES
TABLE 365 GLOBAL MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS [START-UPS/SMES]
11 COMPANY PROFILES (Page No. - 287)
(Business Overview, Products Offered, Recent Developments, MnM View Right to win, Strategic choices made, Weaknesses and competitive threats) *
11.1 KEY PLAYERS
11.1.1 CSL
TABLE 366 CSL: BUSINESS OVERVIEW
11.1.2 GRIFOLS, S.A.
TABLE 367 GRIFOLS, S.A.: BUSINESS OVERVIEW
11.1.3 TAKEDA PHARMACEUTICAL COMPANY LIMITED
TABLE 368 TAKEDA PHARMACEUTICAL COMPANY LIMITED: BUSINESS OVERVIEW
11.1.4 OCTAPHARMA AG
TABLE 369 OCTAPHARMA AG: BUSINESS OVERVIEW
11.1.5 KEDRION S.P.A
TABLE 370 KEDRION S.P.A: BUSINESS OVERVIEW
11.1.6 LFB
TABLE 371 LFB: BUSINESS OVERVIEW
11.1.7 BIOTEST AG
TABLE 372 BIOTEST AG: BUSINESS OVERVIEW
11.1.8 SANQUIN
TABLE 373 SANQUIN: BUSINESS OVERVIEW
11.1.9 CHINA BIOLOGIC PRODUCTS HOLDINGS, INC.
TABLE 374 CHINA BIOLOGIC PRODUCTS HOLDINGS, INC.: BUSINESS OVERVIEW
11.1.10 GC PHARMA
TABLE 375 GC PHARMA: BUSINESS OVERVIEW
11.1.11 BIO PRODUCTS LABORATORY LTD.
TABLE 376 BIO PRODUCTS LABORATORY LTD.: BUSINESS OVERVIEW
11.1.12 JAPAN BLOOD PRODUCTS ORGANIZATION
TABLE 377 JAPAN BLOOD PRODUCTS ORGANIZATION: BUSINESS OVERVIEW
11.1.13 EMERGENT BIOSOLUTIONS
TABLE 378 EMERGENT BIOSOLUTIONS: BUSINESS OVERVIEW
11.1.14 SHANGHAI RAAS BLOOD PRODUCTS CO., LTD.
TABLE 379 SHANGHAI RAAS BLOOD PRODUCTS CO., LTD.: BUSINESS OVERVIEW
11.1.15 INTAS PHARMACEUTICALS LTD.
TABLE 380 INTAS PHARMACEUTICALS LTD.: BUSINESS OVERVIEW
11.2 OTHER COMPANIES
11.2.1 BHARAT SERUMS AND VACCINES LIMITED
11.2.2 SK PLASMA
11.2.3 SICHUAN YUANDA SHUYANG PHARMACEUTICAL CO., LTD.
11.2.4 KAMADA PHARMACEUTICALS
11.2.5 CENTURION PHARMA
11.2.6 ADMA BIOLOGICS, INC.
11.2.7 PLASMAGEN BIOSCIENCES PVT. LTD.
11.2.8 VIRCHOW BIOTECH PRIVATE LIMITED
11.2.9 FUSION HEALTHCARE
11.2.10 HEMARUS THERAPEUTICS LIMITED
11.2.11 BIOPHARMA
11.2.12 PROTHYA BIOSOLUTIONS
11.2.13 HEMOBRÁS
*Details on Business Overview, Products Offered, Recent Developments, MnM View, Right to win, Strategic choices made, Weaknesses and competitive threats might not be captured in case of unlisted companies.
12 APPENDIX (Page No. - 351)
12.1 DISCUSSION GUIDE
12.2 AVAILABLE CUSTOMIZATIONS
12.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
12.4 RELATED REPORTS
12.5 AUTHOR DETAILS
This study involved four major activities in estimating the current size of the plasma fractionation market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of segments and subsegments.
Secondary Research
Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the plasma fractionation market. The secondary sources used for this study include International Plasma Fractionation Association (IPFA), Plasma Protein Therapeutics Association (PPTA), International Plasma Products Industry Association (IPPIA), European Association of the Plasma Products Industry (EAPPI), World Health Organization (WHO), Annual Reports, SEC Filings, Investor Presentations, Expert Interviews, and MarketsandMarkets Analysis. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.
Primary Research
In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess future prospects of the market. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the total size of the plasma fractionation market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
- The key players in the industry and market have been identified through extensive secondary research
- The revenues generated from the plasma fractionation business of leading players have been determined through primary and secondary research
- All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources
Data Triangulation
After arriving at the overall market size from the market size estimation process, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Report Objectives
- To define, describe, and forecast the global plasma fractionation market based on the product, application, end user and region
- To provide detailed information regarding the major factors influencing the growth of the market (such as drivers, restraints, challenges, and opportunities)
- To strategically analyze micromarkets with respect to individual growth trends, future prospects, and contributions to the overall plasma fractionation market
- To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to five main regions, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa
- To strategically profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
- To track and analyze competitive developments such as acquisitions, product launches, expansions, agreements, partnerships, and R&D activities in the plasma fractionation market.
Available Customizations
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:
Company Information
- An additional five company profiles
Growth opportunities and latent adjacency in Plasma Fractionation Market
Informative; however, the study requires more details.